Posted by Michael Wonder on 21 Feb 2017
BPS-804 accepted for EMA adaptive pathways programme
20 February 2017 - Mereo BioPharma Group is pleased to announce that BPS-804 has been accepted to participate in the European Medicines Agency’s Adaptive Pathways programme.
BPS-804 is being developed for the treatment of osteogenesis imperfecta (brittle bone disease). It has been granted orphan drug designation by both the European Commission and the U.S. FDA.
